ClinicalTrials.gg
Active, not recruitingNCT07113561PRO-FITUpdated Oct 23, 2026

Effects of a High-protein Diet and Resistance Training on Fat-mass Loss Maintenance

An interventional study of High-protein diet and resistance training and Balanced control diet in Obesity (Body Mass Index >30 kg/m2), sponsored by Norwegian University of Science and Technology. Active, not recruiting at 1 site in Norway. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Norwegian University of Science and Technology · Not applicable, Interventional, and Treatment

How we know

Updated Oct 23, 2026Primary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Obesity by Norwegian University of Science and Technology — none open to participants now, 3 under way, none of them phase 3. Obesity · Norwegian University of Science and Technology.

Planned enrollment
12th of 37
60 · median 46
Started
2025
with 1 other
No phase
37 of 38
none open now
Registered
38th of 38
by date

Among the 38 studies in Obesity by Norwegian University of Science and Technology, this one is the 12th largest by planned enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2025, is one of 37 with no phase, and was the 38th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

None of the 38 studies in Obesity by Norwegian University of Science and Technology is open now. The open studies under Obesity, anywhere →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 38 studies in Obesity by Norwegian University of Science and Technology as a file.
02

Study summary

This clinical trial investigates whether a high-protein diet combined with resistance training is more effective than a standard low-calorie diet for maintaining fat mass loss in individuals with obesity.

A total of 60 adults with obesity (BMI ≥30 kg/m²) will be randomly assigned at baseline to one of two groups:

  1. A control group receiving a balanced low-calorie diet.
  2. An intervention group receiving a high-protein, low-calorie diet and supervised resistance training.

All participants will follow their assigned low-energy diets for the first 10 weeks, which constitutes the weight loss phase. The subsequent 42 weeks comprise the weight maintenance phase, where participants will follow an energy-balanced diet adapted to their individual needs and continue in their assigned group.

The intervention group will also complete supervised resistance training three times per week during the first 10 weeks, with continued follow-up throughout the maintenance phase.

Assessments will take place at baseline, week 11, 6 months, and 12 months, and include measurements of fat and lean mass, resting metabolic rate, appetite hormones, glucose metabolism, inflammation, gut microbiota and its metabolites, hedonic appetite, eating behavior, and quality of life and physical function. Participants will also provide food intake records, physical activity dat.

The primary aim is to determine whether the combined high-protein diet and resistance training intervention results in greater long-term fat mass loss and muscle mass preservation than the control diet. Secondary aims include effects on appetite regulation, eating behavior, metabolic health, and patient-reported outcomes.

The study is conducted at NTNU and St. Olavs Hospital in Trondheim, Norway, and registered under the acronym PRO-FIT.

03

Conditions studied

  • Obesity (Body Mass Index >30 kg/m2)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • equal to or above 30
  • Sedentary lifestyle (\<150 minutes moderate physical activity per week and no habitual resistance training (\< once weekly)
  • \< 2 kg body weight change in the 3 months prior to study commencement
  • high motivation for lifestyle change
  • not currently enrolled in any other obesity or behavioral change program

Exclusion criteria

Exclusion Criteria:

  • Previous or planned bariatric surgery
  • Current or planned usage of medications or anti-obesity drugs known to influence energy metabolism or appetite
  • Diabetes (type 1 and 2)
  • Women in menopause or women
  • Existing cancer diagnosis
  • Renal disease
  • Substance abuse
  • Eating disorders
  • Allergies, or intolerances to ingredients in meal packs/supplements intended for use in the study
  • Mobility/physical constrains or musculoskeletal issues that could impede participation in the resistance training program
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    High-protein diet and resistance training

    Intervention group: Participants will undergo a low-calorie high-protein diet for 10 weeks, followed by a maintenance phase up to the 1-year mark. This group will also participate in supervised resistance training sessions.

    Other: High-protein diet and resistance training

  • Experimental
    Balanced control diet

    Control group: Participants will undergo a balanced low-calorie diet for 10 weeks, followed by a maintenance phase up to the 1-year mark. This group will not receive any active exercise intervention.

    Other: Balanced control diet

Interventions

  • OtherHigh-protein diet and resistance training

    Participants will consume a low-energy high-protein diet for 10 weeks, and participate in supervised resistance training sessions. They will continue a maintenance diet up until the 1 year mark, with bi-monthly follow ups on diet and exercise.

  • OtherBalanced control diet

    Participants will consume a balanced low-energy diet for 10 weeks, and continue a balanced maintenance diet with bi-monthly follow ups up until the 1-year mark No active exercise intervention.

06

What researchers measure

Primary outcomes

  1. Fat-mass

    Fat-mass will be estimated using a dual-energy absorptiometry (DXA, GE Healthcare Lunar).

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

Secondary outcomes

  1. Body weight and -composition

    Body weight and -composition will be estimated with dual-energy absorptiometry (DXA, GE Healthcare Lunar) (primary outcomes) and bioimpedance (InBody 770). Compartments that will be estimated are: total body weight, Fat-mass, fat-free mass, bone mineral density, visceral fat, muscle mass, body water, as well as segmental analysis of body weight and composition.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, 26 and at 52 weeks.

  2. Resting metabolic rate

    Resting metabolic rate will be measured in the fasted state using an indirect calorimetry (Quark RMR, Cosmed).

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  3. Leeds food preference questionnaire

    Food reward and -preferences will be assessed with the Leeds Food Preference Questionnaire (LFPQ), in the fasted state and immediately after the test meal. The LFPQ is a computerized behavioral task that provides measures of 'explicit liking' and explicit and 'implicit wanting' for sensory and nutrient dimensions of foods using food images.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  4. Dutch Eating Behavior Questionnaire

    The Dutch Eating Behavior Questionnaire measures restrained, external and emotional eating. Emotional eating can be divided into two sub-categories: diffuse emotions and clearly labelled emotions. The greater score, the greater external/emotional eating.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 26 and 52 weeks.

  5. Power of Food Scale

    The Power of food scale is a psychometric evaluation that measures an individual's preoccupation with wanting of highly palatable foods. The PFS consists of a 15-item list that measures hedonic hunger (food-related thoughts that are unrelated to homeostatic need). The higher the PFS score, the greater the hedonic hunger.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 26 and 52 weeks.

  6. Three Factor Eating Questionnaire

    The Three Factor Eating Questionnaire measures three different dimensions: restraint, disinhibition, and hunger. The greater score, the stronger is the trait/behavior.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 26 and 52 weeks.

  7. Ghrelin

    Blood will be collected in the fasted state (minute 0), and then at intervals after a standardized breakfast (minute 15, 30, 45, 60, 90, 120 and 150) and analyzed for acylated ghrelin concentrations.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  8. GLP-1

    Blood will be collected in the fasted state (minute 0), and then at intervals after a standardized breakfast (minute 15, 30, 45, 60, 90, 120 and 150) and analyzed for total GLP-1 concentrations.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  9. CCK

    Blood will be collected in the fasted state (minute 0), and then at intervals after a standardized breakfast (minute 15, 30, 45, 60, 90, 120 and 150) and analyzed for CCK concentrations.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  10. PYY

    Blood will be collected in the fasted state (minute 0), and then at intervals after a standardized breakfast (minute 15, 30, 45, 60, 90, 120 and 150) and analyzed for total PYY concentrations.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  11. Insulin

    Blood will be collected in the fasted state (minute 0), and then at intervals after a standardized breakfast (minute 15, 30, 45, 60, 90, 120 and 150) and analyzed for insulin concentrations.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  12. C-peptide

    Blood will be collected in the fasted state (minute 0), and then at intervals after a standardized breakfast (minute 15, 30, 45, 60, 90, 120 and 150) and analyzed for c-peptide concentrations.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  13. Glucose

    Blood will be collected in the fasted state (minute 0), and then at intervals after a standardized breakfast (minute 15, 30, 45, 60, 90, 120 and 150) and analyzed for glucose concentrations.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  14. GIP

    Blood will be collected in the fasted state (minute 0), and then at intervals after a standardized breakfast (minute 15, 30, 45, 60, 90, 120 and 150). Plasma samples will be stored and analyzed for GIP concentrations depending on additional funding.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  15. Glucagon

    Blood will be collected in the fasted state (minute 0), and then at intervals after a standardized breakfast (minute 15, 30, 45, 60, 90, 120 and 150). Plasma samples will be stored and analyzed for glucagon concentrations depending on additional funding.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  16. IL-6

    Blood will be collected and plasma samples will be stored and analyzed for IL-6 concentrations depending on additional funding.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  17. TNF-alfa

    Blood will be collected and plasma samples will be stored and analyzed for TNF-alfa concentrations depending on additional funding.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  18. CRP

    Blood will be collected in the fasted state (minute 0), and analyzed for CRP.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  19. Triglycerides

    Blood will be collected in the fasted state (minute 0), and analyzed for triglycerides.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  20. HbA1C

    Blood will be collected in the fasted state (minute 0), and analyzed for HbA1C

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  21. HDL

    Blood will be collected in the fasted state (minute 0), and analyzed for high-density lipoprotein

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  22. LDL

    Blood will be collected in the fasted state (minute 0), and analyzed for low-density lipoprotein

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  23. Total cholesterol

    Blood will be collected in the fasted state (minute 0), and analyzed for total choesterol.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  24. Hemoglobin

    Blood will be collected in the fasted state (minute 0), and analyzed for hemoglobin.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  25. Gut microbiota

    Fecal samples will be collected and comprehensive microbiota profiling using DNA-based sequencing will be performed.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  26. Short-chain fatty-acids

    Fecal samples will be collected and acetate, propionate, and butyrate will be quantified by gas chromatography-mass spectrometry (GC-MS)

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  27. IWQOL-lite

    The Impact of Weight on Quality of Life (IWQOL)-Lite questionnaire will be used to assess obesity-specific quality of life and includes 5 subcategories: physical function, self-compassion, sexual life, public distress and work. In addition, the total quality of life score will be assessed. Higher score, better quality of life.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  28. Short Form-36 (SF-36)

    The SF-36, or Short Form 36, is a 36-item questionnaire used to assess a person's self-reported health-related quality of life. It measures eight health concepts: physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional health, and mental health where a higher score represents better health.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  29. Estimated one-repetition maximum (1RM)

    1RM will be calculated using submaximal lifts performed to muscular failure within 4-8 repetitions.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 26- and 52 weeks.

  30. Patient specific functional Scale

    The Patient Specific Functional Scale is a patient-specific instrument. This means that the patient selects activities (three to five) that they have difficulty performing due to their illness or injury, and then rates their ability to perform these activities.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  31. Force development- and peak force

    A one-repetition max tests and a force development- and peak force task will be undertaken on a force platform (Kistler, Switzerland) installed on a leg press device.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  32. Subjective appetite

    Subjective ratings of appetite (hunger, fullness, desire to eat, and prospective food consumption) will be measured in fasting (minute 0) and then at minute 15, 30, 60, 90, 120 and 150 after the standardized test meal.

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  33. Blood pressure

    Blood pressure will be measured in units of millimeters of mercury (mmHg)

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

Other outcomes

  1. Food records

    Participants will quantify their daily energy intake by logging self-reported food diaries. Energy intake and macronutrient distribution will be calculated based on reported foods and quantitates.

    Time frame: Before start of intervention, during weight loss phase, at 6 month follow up, and prior to assessments at week 52.

  2. Ketone bodies

    In addition to food logs, ketone bodies will be measured for compliance to diet and to account for potential nutritional induced ketosis. Acetoacetate will be measured in urine using Bayer ketostix and betahydroxtbutyrate using a freestyle libre ketone meter.

    Time frame: At baseline assessments, during weight loss phase( baseline to week 11), at week 11 assessments, at 6 months and assessments at week 52

  3. Plasma samples

    Plasma samples will also be stored for exploratory analyses later

    Time frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.

  4. Adherence to exercise intervention

    Attendance to scheduled training sessions will be recorded, together with type of exercise, sets, reps and loads.

    Time frame: During weight loss phase( baseline to week 11), and during maintenance phase up until week 52

  5. Physical activity levels

    Physical activity levels will be estimated using actigraphs for 7-day periods.

    Time frame: Before and during weight loss phase( baseline to week 11), at 26 and 52 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Participant-level data will not be made publicly available due to the sensitive nature of the health-related and biological data collected. Data may be shared with approved collaborators for analyses within the scope of the project, subject to applicable ethical approvals, participant consent, institutional procedures, and data-sharing agreements. Any use beyond the approved project scope will require additional approvals and, where applicable, new participant consent.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jan 2027, 16 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 16 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2025
First posted
Aug 8, 2025
StartActual
Sep 16, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Dec 2027
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 removed
What changed in the outcomes
  • RemovedFat-free massTime frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
Oct 23, 2026
Secondary outcomes
1 removed
What changed in the outcomes
  • RemovedAnthropometric variablesTime frame: From enrollment at baseline , after 10 weeks of weight loss phase, 26 and at 52 weeks.
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Primary outcomes 1 removed
    What changed in the outcomes
    • RemovedFat-free massTime frame: From enrollment at baseline , after 10 weeks of weight loss phase, and at 52 weeks.
    Secondary outcomes 1 removed
    What changed in the outcomes
    • RemovedAnthropometric variablesTime frame: From enrollment at baseline , after 10 weeks of weight loss phase, 26 and at 52 weeks.
    + 2 other changes: verification date and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07113561
Collaborators
University of Alabama at Birmingham, University of Leeds, Appetite Control and Energy Balance Research, University of Copenhagen, St. Olavs Hospital
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Sep 16, 2025
Primary completion
Jan 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion